Ultrasound imaging evaluation of the clinical efficacy of risperidone and olanzapine in treating schizophrenia and their effects on liver function and blood lipids in patients
10.3760/cma.j.cn341190-20241023-01363
- VernacularTitle:肝脏B超影像学评价利培酮与奥氮平治疗精神分裂症的临床效果及对患者肝脏、血脂的影响
- Author:
Weiwei CHEN
1
;
Chenlin ZHANG
Author Information
1. 宁波市精神病院特检科，宁波 315032
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Ultrasonography;
Fatty liver;
Dyslipidemias;
Drug-induced liver injury, chronic;
Root cause analysis
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(8):1192-1196
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze ultrasound imaging evaluation of the clinical efficacy of risperidone and olanzapine in treating schizophrenia, as well as their effects on liver function and blood lipids, providing a basis for reducing the occurrence of liver and lipid abnormalities after pharmacological treatment for schizophrenia.Methods:The study was conducted with a sample size of 85 cases. A total of 50 patients with schizophrenia admitted to Ningbo Psychiatric Hospital from January to December 2023 were retrospectively collected. These patients were divided into two groups based on their treatment: the risperidone group and the olanzapine group, with 25 patients in each group. Additionally, 35 healthy individuals who underwent medical examinations during the same period were selected as the control group. Liver ultrasound and blood lipid levels were assessed in all three groups. The detection rates of fatty liver and dyslipidemia were compared among the groups. The positive rates of liver ultrasound examination were compared between the risperidone and olanzapine groups.Results:The detection rates for fatty liver and elevated blood lipids in the risperidone group [24.00% (6/25), 12.00% (3/25)] and control group [8.57% (3/35), 2.86% (1/35)] were significantly higher than those in the olanzapine group [36.00% (9/25), 24.00% (6/25), χ2 = 6.74, 6.28, both P < 0.05). In the olanzapine group, the incidence rates of simple fatty liver, fatty liver with gallstones and cholecystitis, and diffuse changes were 60.00% (15/25), 40.00% (10/25), and 40.00% (10/25), respectively, which were significantly higher than those in the risperidone group [28.57% (10/35), 14.29% (5/30), 5.71% (2/35), χ2 = 5.93, 5.14, 10.71, all P < 0.05]. Conclusions:For patients with schizophrenia who are continuously receiving olanzapine treatment, implementing regular liver ultrasound monitoring can effectively prevent and mitigate the potential risk of drug-induced liver damage, ensuring the safety and efficacy of the treatment process.
